Evidence map›Paper›PMID 15342497›Full record

ArticleGenetics2004

Selection in context: patterns of natural selection in the glycoprotein 120 region of human immunodeficiency virus 1 within infected individuals.

Alan R Templeton, Rebecca A Reichert, Anton E Weisstein, Xiao-Fang Yu, Richard B Markham

Abstract read
In one paragraph

Article in Genetics, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. The evolution of HIV: inferences using phylogenetics.Molecular phylogenetics and evolution · 2012
    Review
  2. Has human evolution stopped?Rambam Maimonides medical journal · 2010
    Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Neutralizing antibody responses drive the evolution of human immunodeficiency virus type 1 envelope during recent HIV infection.Proceedings of the National Academy of Sciences of the United States of America · 2005
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Alan R TempletonDepartment of Biology, Washington University, St. Louis, Missouri 63130-4899, USA. temple_a@westl.edu
Rebecca A Reichert
Anton E Weisstein
Xiao-Fang Yu
Richard B Markham

Funding

NATURAL HISTORY OF HIV INFECTION IN INJECTION DRUG USERSR37DA004334 · NIDA · JOHNS HOPKINS UNIVERSITY · PI KIRK, GREGORY D · 1997 to 2006
$9.0M
THE NATURAL HISTORY OF HIV INFECTION AMONG DRUG USERSR01DA004334 · NIDA · JOHNS HOPKINS UNIVERSITY · PI KIRK, GREGORY D · 1987 to 2011
$7.6M
Natural History of HIV Infection In Injection Drug UsersR56DA004334 · NIDA · JOHNS HOPKINS UNIVERSITY · PI KIRK, GREGORY D · 2012 to 2013
$3.2M
DRUG ABUSE AND RESISTANCE TO ANTIRETROVIRAL THERAPYR01DA013347 · NIDA · JOHNS HOPKINS UNIVERSITY · PI MARKHAM, RICHARD B. · 2000 to 2004
$1.9M
IMPACT OF RECOMBINATION IN HIV-1 ON INTRAHOST EVOLUTIONR01GM060730 · NIGMS · JOHNS HOPKINS UNIVERSITY · PI MARKHAM, RICHARD B. · 1999 to 2002
$913k
HIV 1 IMMUNE ACTIVATION AND PATHOGENESIS IN DRUG USERSR01DA009973 · NIDA · JOHNS HOPKINS UNIVERSITY · PI MARKHAM, RICHARD B. · 1995 to 1998
–
PHENOTYPIC/GENOTYPIC VARIATION IN HIV INFECTIONR01DA009541 · NIDA · JOHNS HOPKINS UNIVERSITY · PI YU, XIAO-FANG · 1994 to 1997
–
NIDA NIH HHS DA 04334NIDA NIH HHS DA 09541NIDA NIH HHS DA 09973NIDA NIH HHS R01 DA013347NIGMS NIH HHS R01 GM60730
6 · The paper itself

Abstract

Evolution of the HIV-1 V3 loop was monitored in 15 subjects over a period of 5 years at approximately 6-month intervals. Putative recombination was detected in many of the sequences. Evolutionary trees were estimated from the nonrecombinant viral sequences found in each individual. Selection and altered demographic regimes were detected with logit and other contingency analyses in a highly context-dependent fashion. Mutations leading to amino acid substitutions are subject to positive selection over a broad range of clinical conditions in the nonsyncytium-inducing (NSI) form, and the growth rates of the NSI strains and their level of genetic subdivision change little in going from a healthy immune system to a severely compromised immune system. In contrast, the SI form has a significant increase in growth rate as the immune system goes from healthy to compromised, particularly in those subjects who did not receive any antiviral drug therapy. This increase in SI growth rate results in a significant growth advantage of SI over NSI when the immune system is compromised. The SI strains also show more demographic subdivision when the immune system is healthy than when the immune system is compromised, and the SI form has greater demographic subdivision than NSI in subjects with healthy immune systems who also are not receiving antiviral drug therapy. Positive selection on amino-acid-changing mutations weakens and then intensifies again in the SI strains in going from healthy to compromised immune systems. These patterns are consistent with other studies that suggest that NSI strains inhibit replication of SI strains, that the V3 loop is more hidden from the immune system in the NSI form, that evolution in the V3 loop influences cell tropism and coreceptor usage, that substrate for replication of SI forms increases as the disease progresses, and that death of CD8 cells is influenced by the type of coreceptor usage typically found in SI but not in NSI strains. Finally, the transition between NSI and SI forms is associated with a burst of evolutionary change due to strong positive selection at sites other than those that define the NSI/SI phenotypes.

Indexed as

Selection, GeneticAcquired Immunodeficiency SyndromeCD4 Lymphocyte CountCD8-Positive T-LymphocytesDemographyHaplotypesHIV-1HIV Envelope Protein gp120HIV SeropositivityHumansLymphocyte CountModels, GeneticMolecular Sequence DataHIV Envelope Protein gp120

Identifiers

PMID15342497
PMCPMC1470982

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.